Summary
The response includes multiple factual claims (indications, mechanism, liver enzyme elevations, monitoring, and dosing adjustments) that are not supported by the provided prescribing information excerpts. The only label-supported content in the provided text concerns increased all-cause mortality and limitation of use for hospital/ventilator-associated pneumonia; none of the listed claims address those specifically. Therefore, overall alignment cannot be verified from the supplied label material.
Category Scores
Accurate Statements
The label excerpt indicates tigecycline is used for approved indications including cSSSI, cIAI, and CABP.
Supported indirectly by Section 5.1/6.1 text: mortality analysis in all trials conducted for approved indications (cSSSI, cIAI, and CABP).
Unsupported Statements
Tigecycline (Tygacil) is a glycylcycline antibiotic approved by the FDA in 2005.
No approval year or antibiotic class description is provided in the supplied excerpts.
Tigecycline is approved by the FDA for treatment of complicated skin and skin structure infections (cSSSI).
The excerpt only references cSSSI as an approved indication in a mortality analysis; it does not provide the indication statement itself to support this claim as phrased.
Tigecycline is approved by the FDA for treatment of complicated intra-abdominal infections (cIAI).
The excerpt references cIAI only as part of mortality analysis for approved indications; it does not provide an explicit approval/indication statement.
Tigecycline is approved by the FDA for treatment of community-acquired bacterial pneumonia (CABP).
The excerpt references CABP only as part of mortality analysis for approved indications; it does not provide an explicit approval/indication statement.
Tigecycline works by inhibiting protein synthesis in bacteria.
Mechanism of action is not described in the provided excerpts.
Tigecycline can be associated with liver enzyme elevations.
Liver enzyme elevations (including AST/ALT) are not mentioned in the provided excerpts.
Tigecycline has been associated with liver enzyme elevations including AST in clinical trials and post-marketing surveillance.
No AST/ALT or liver enzyme information is present in the provided excerpts.
In clinical trials, tigecycline was associated with liver enzyme elevations in 3.4% of patients.
No such percentage or liver enzyme incidence is present in the provided excerpts.
The most common liver enzyme elevations with tigecycline include AST and ALT elevations.
No liver enzyme frequency hierarchy is present in the provided excerpts.
AST and ALT elevations in patients treated with tigecycline were typically mild to moderate in severity.
No liver enzyme severity information is present in the provided excerpts.
Tigecycline has been associated with liver enzyme elevations, including AST, in 2.3% of patients in clinical trials.
No such percentage is present in the provided excerpts.
Tigecycline can cause liver enzyme elevations, including AST, in some patients.
No liver enzyme or AST statements are present in the provided excerpts.
Liver enzyme elevations, including AST, with tigecycline are typically mild to moderate in severity.
No severity statements for AST/ALT are present in the provided excerpts.
Liver enzyme elevations with tigecycline often resolve on their own.
No liver enzyme resolution information is present in the provided excerpts.
Older adults may be more susceptible to liver enzyme elevations with tigecycline.
No age-related risk information for liver enzymes is present in the provided excerpts.
Patients with pre-existing liver disease may be at increased risk for liver enzyme elevations with tigecycline.
No statements about pre-existing liver disease and liver enzyme elevations are present in the provided excerpts.
Certain concomitant medications, such as acetaminophen, can increase the risk of liver enzyme elevations with tigecycline.
Drug interaction information (including acetaminophen) is not present in the provided excerpts.
Healthcare providers should monitor AST levels regularly in patients receiving tigecycline to identify potential liver enzyme elevations early.
No monitoring recommendations for AST are present in the provided excerpts.
Dosing adjustments may be necessary in patients with pre-existing liver disease receiving tigecycline.
No dosing adjustment guidance is present in the provided excerpts.
Dosing adjustments may be necessary in patients taking concomitant medications that increase the risk of liver enzyme elevations receiving tigecycline.
No dosing adjustment guidance based on concomitant medications is present in the provided excerpts.
Contradictions
Important Omissions
Boxed Warning content regarding increased all-cause mortality and the reserve-use instruction (i.e., reserve use when alternative treatments are not suitable).
Importance:
High
Limitation of use: not indicated for hospital-acquired or ventilator-associated pneumonia; and the associated concern (greater mortality/decreased efficacy in that setting).
Importance:
High
Warnings/clinical trial mortality imbalance details (including ventilator-associated pneumonia sub-group effects) that are present in the provided excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The response asserts multiple liver-enzyme-related and dosing/monitoring claims that are not supported by the provided prescribing information excerpts, while omitting the key boxed warning and limitation-of-use statements included in those excerpts. This combination indicates a high risk of inaccurate labeling alignment when using the response as a surrogate for label content.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims (indications as stated, mechanism, liver enzyme elevations with rates/severity, interactions/acetaminophen, monitoring, and dosing adjustments) are unsupported by the supplied FDA label excerpts; key boxed warning and limitation-of-use content are omitted.
Suggested Improvement
Limit statements to what is present in the provided label text (e.g., increased all-cause mortality boxed warning and reserve-use instruction; limitation of use for hospital/ventilator-associated pneumonia; and the mortality imbalance details). Provide label-supported citations for any additional safety or monitoring claims such as AST/ALT, severity, resolution, populations at increased risk, or drug interactions.